Rahul Seth, D.O.
`Assistant Professor
`
`SUNY Upstate Medical University
`750 East Adams Street
`
`Syracuse, New York 13210
`Telephone — 315-464-8200
`Email — sethr@,unstate.edu
`
`PERSONAL DATA:
`
`Born: April 1, 1970
`Citizenship: United States
`Marital Status: Married
`Children: Two
`
`EMPLOYMENT:
`
`2009 — Present
`
`2005 — 2009
`
`AFFILIATIONS:
`
`2009 — Present
`
`2009 — Present
`
`EDUCATION:
`
`1995 — 1999
`
`1992-1995
`
`Assistant Professor: SUNY Upstate Medical University
`Syracuse, New York
`Practicing Oncologist: Cancer and Blood Specialist of Long Island
`Greenlawn, New York
`
`Department of Medicine MSG at SUNY HSC at Syracuse, Inc., d/b/a
`University Physicians, 140 West 6”‘ Street, Suite 110, Oswego, NY 13126
`Department of Medicine MSG at SUNY HSC at Syracuse, Inc., d/b/a
`University Physicians, 1000 East Genesee Street, Suite 403
`Syracuse, NY 13210
`
`New York College of Osteopathic Medicine, Old Westbury, New York
`Doctor of Osteopathy
`Brown University, Providence, Rhode Island
`Master of Science, Biochemistry & Toxicology
`Thesis: Vitamine A in Murine Reproduction
`Mentor: Kim Boekelheide, M.D., Ph.D.
`
`1988-1991
`
`Carnegie Mellon University, Pittsburgh, Pennsylvania
`Bachelor of Science, Biology
`
`POSTDOCTORAL TRAINING:
`
`2002-2005
`
`1999-2002
`
`Hematology & Oncology Fellowship
`Department of Oncology and Hematology
`Stony Brook University Hospital, Stony Brook, New York
`Internal Medicine Residency
`-
`General Medicine Department
`ony Brook University Hospital, Stony Brook, New York
`
`MYLAN - EXHIBIT 1003
`
`00001
`
`00001
`
`MYLAN - EXHIBIT 1003
`
`

`
`COMMITTEES:
`
`2009 — Present
`2004 — 2005
`2004 — 2005
`2002 —— 2005
`2002 — 2005
`
`PUBLICATIONS:
`
`IRB Committee, SUNY Upstate Medical University
`Quality of Life Committee
`Bone Marrow Transplant Advisory Committee
`Pain Management Sub-Committee
`Anti-Emetic Sub-Committee
`
`“Granisetron vs. Dolastron for acute chemotherapy—induced nausea and vomiting (CINV) in high
`and moderately high emetogenic chemotherapy: an open-label pilot study” Tan M., Xu R., Seth
`R., Current Medical Research and Opinion, 20(6):878-882, 2004.
`
`“Guide to Medical Oncology at Stony Brook University Hospital” Xu R., Seth R., Tan M., et al:
`First Edition, Stony Brook University Press, July 2001.
`
`“Male infertility caused by epidiymal dysfunction in transgenic mice expressing a dominant
`negative mutation of retinoic acid receptor alpha l” Costa SL, Boekelheide K, Vnaderhyden BC,
`Seth R., et al., Biology ofReproduction 56(4): 985-990, 1997.
`
`“Malignant phyllodes tumor of the breast presenting with hypoglycemia: a case report and
`literature review" Pacioles T, Seth R, Orellana C, John I, Panuganty V, Dhaliwal R, Cancer
`Manag Res, 6:467—73, 2014.
`
`POSTERS:
`
`“Hospital wide Conversion of Epoetin alfa to Darbepoetin alfa: University Hospital Experience”
`Abstract/Poster Presentation at ASHIP Mid—Year Clinical Meeting, Tan M., Seth R., Weber S.,
`Chem B. New Orleans, 2003
`
`“Efficacy of Kytril versus Anzemet for Highly Emetogenic Chemotherapy” Abstract/Poster
`presentation at MASCC Annual Meeting, Tan M., Seth R., Xu R. Boston 2002
`
`LECTURES:
`
`November 2003
`
`June 2003
`
`June 2003
`
`January 2003
`
`November 2002
`
`“Management of Cancer Pain” Stony Brook University Department of
`Oncology,
`“Velcade and Clinical Application” Stony Brook University Department
`of Oncology
`“Current Opinion and Updates in Colon Cancer” Stony Brook University
`Department of Oncology
`“Crystal Storing Histiocytes” Stony Brook University Department of
`Oncology
`Anemia Management in Cancer Patients” Oncology Nursing Association
`Monthly Meeting
`
`00002
`
`00002
`
`

`
`RESEARCH:
`
`2003 — Present
`
`Autoimmune Disease Response to Bone Marrow Transplant, Dr. Douglas
`Gladstone
`
`2001 — 2002
`
`Dendritic Cells Response to Cytotoxic Drugs, Dr. Amitabha Mazumder
`
`FUNDED RESEARCH:
`
`Otsuka Protocol 287-11-201 — Phase 2 Placebo-Controlled Double-Blind Trial of Dasatinib
`
`Added to Gemcitabine for Subjects with Locally- Advanced Pancreatic Cancer
`
`Janssen Research & Development, LLC Protocol ET743-SAR-2007 — A Randomized Controlled
`Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced
`Liposarcoma or Leiomyosarcoma
`
`EMD Serono Protocol EMR200592-001 — A Randomized, Double—Blind, Phase III Study of the
`Efficacy and Safety of Gemcitabine in Combination with TH-3 02 Compared with Gemcitabine
`in Combinationwith Placebo in Previously Untreated Subjects with Metastatic or Locally
`Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO: TH-3 02 in the treatment of
`Metastatic or locally Advanced unrESectable pancreaTic adenocaRcinOma)
`
`Bayer Protocol 15983 — A Randomized, Double—B1ind, Placebo-Controlled Phase III Study of
`Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After
`Curative Treatment of Liver Metastases
`
`Celgene/PPD ABI-007-PANC-003- A Phase 3, Multicenter, Open—Label, Randomized Study of
`Nab®—Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects
`with Surgically Resected Pancreatic Adenocarcinoma
`
`Celgene Health-Related Quality of Life among People with Metastatic Pancreatic Cancer
`Eleison: EP-GF-301- A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide
`Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma
`Previously Treated with Gemcitabine
`
`ACCRU - BBI608-336: A Phase III Randomized Double—Blind, Placebo-Controlled Clinical
`Trial of BBI608 plus Weekly Paclitaxel vs Placebo plus Weekly Paclitaxel in Adult Patients with
`Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma
`
`Prometheus — 10PLK 13 — PROCLAIM: Proleukin Observation Registry to Evaluate the
`Treatment Patterns and Clinical Response in Malignancy
`
`Prometheus — 12PLK02 - Open—Label, Randomized, Multi-Center Study Comparing the
`Sequence of High Dose Aldesleukin (Interleukin—2) and Ipilimumab (Yervoy®) in Patients with
`Metastatic Melanoma
`
`00003
`
`00003
`
`

`
`Merck — 045-02 — A Phase 3 Trial of Pembrolizumab (MK-3475) vs Paclitaxel or Docetaxel,
`Vinflunine in Recurrent/Progressive Metastatic Urothelial Cancer.
`
`OncoMed - M18-006 — YOSEMITE: A 3—Arm Phase 2 Double—Blind Randomized Study of
`Gemcitabine, Abraxane® Plus Placebo versus Gemcitabine, Abraxane® plus 1 or 2 Truncated
`Courses of Demcizumab in Subjects with 15‘-line Metastatic Pancreatic Ductal Adenocarcinoma
`
`Celgene/PPD — ABI-007-PANC-007 - nab-Paclitaxel (Abraxane®) plus gemcitabine in subjects
`with locally advanced pancreatic cancer (LAPC): An international, open—label, multi—center,
`phase 2 study (LAPACT)
`
`Immunomedics - IMMU 107-04 - An International, Multi—Center, Double—Blind, Randomized,
`Phase III Trial of 9°Y-Clivatuzumab Tetraxetan plus Low—Dose Gemcitabine Versus Placebo
`plus Low—Dose Gemcitabine in Patients with Metastatic (Stage IV) Pancreatic Adenocarcinoma
`Who Received at Least Two Prior Treatments (PANCRIT—l)
`
`BOARD CERTIFICATION:
`
`2006 — 2016 Oncology Board Certified
`
`00004
`
`00004